The Rad9 gene is evolutionarily conserved from yeast to humans and plays crucial roles in genomic maintenance, DNA repair, and cell cycle checkpoint controls. However, the function of this gene with respect to tumorigenesis is not well-understood. A Rad9-null mutation in mice causes embryonic lethality. In this study, we created mice in which mouse Rad9, Mrad9, was deleted only in keratinocytes to permit examination of the potential function of the gene in tumor development. Mice with Mrad9 +/À or Mrad9
Introduction
Cells are constantly exposed to endogenous and exogenous conditions that cause stresses and can induce genomic DNA lesions. Eukaryotic cells have evolutionarily conserved mechanisms that monitor and coordinate cell cycle progression, through checkpoint control activities, with repair of DNA damage. Mutations in genes that play roles in cell cycle checkpoint control and DNA repair are often associated with tumorigenesis. For example, targeted deletion of p53, Brca1, or Atm cell cycle checkpoint genes enhances tumor development (1) (2) (3) (4) (5) . Rad9 plays important roles in multiple cell cycle checkpoint controls and DNA repair (6) (7) (8) . Hence, Rad9 is likely a gatekeeper gene that prevents cancer development by promoting repair of DNA damage before deleterious effects ensue.
Several recent studies showed that Rad9 was aberrantly expressed in tumors. High expression was detected in human non-small cell lung carcinomas (9) and breast tumors (10) . A significantly higher frequency of a single nucleotide polymorphism was observed at the second position of codon 239 (His/Arg heterozygous variant) in human non-small cell lung carcinomas (11) . In contrast, Rad9 expression levels were found to be lower in prostate cancers in an analysis of three pairs of prostate normal/ cancer tissue (12) but a much more extensive analysis found the opposite to be true (13) . In fact, aberrantly high levels of Rad9 have been functionally linked to prostate cancer. Combined haploinsufficiency for mouse atm and Mrad9 causes sensitivity to the morphologic transformation of mouse embryonic fibroblasts by ionizing radiation, whereas haploinsufficiency of Mrad9 alone does not confer a predisposition to transformation (14) . The aforementioned studies established a correlation between cancer development and abnormal Rad9 expression or polymorphism. With respect to expression, aberrantly high or low levels of the protein can predispose to carcinogenesis. However, it remains unclear whether this effect on cancer development is significant for other cancer types, or what the underlying molecular mechanism might be.
A homozygous Rad9-null mutation causes mouse embryonic lethality (15) ; thus, this animal model cannot be used to test whether Rad9 deletion influences tumorigenesis. In this study, we constructed mice selectively deleted for Mrad9 in keratinocytes, thereby circumventing issues related to animal viability. Mice with Mrad9 +/À or Mrad9 À/À keratinocytes showed no overt, spontaneous, morphologic defects. However, the application of 7,12-dimethylbenzanthracene (DMBA) to skin induced a dramatically higher rate of tumor formation in Mrad9 À/À mice than in Mrad9 +/+ or Mrad9 +/À controls. Isolated Mrad9 À/À keratinocytes showed enhanced DNA lesions compared with Mrad9 +/+ or Mrad9 +/À keratinocytes. The Mrad9 À/À cells had aberrant cell cycle distribution and an increased rate of apoptosis. These data suggest that Mrad9 is critical for maintaining genomic stability and preventing tumor development.
Materials and Methods
Mouse strains and genotyping. To create skin-conditional Mrad9 knockout mice, Mrad9
Tar/Tar (15) 129SvEv strain animals were mated to Keratin 5-Cre transgenic mice in which Cre expression is under the control of the Keratin 5 promoter specifically activated in keratinocytes (16) . Keratin 5-Cre transgenic mice were originally created using Chinese KM mice and then mated with C57BL/6 mice at least for 10 generations, so it is a hybrid of KM and C57BL/6 mice but with more C57BL/6 genetic background. Methods for DNA isolation and PCR genotyping of mouse tissues as well as isolated keratinocytes for the Mrad9-loxP loci and Cre-mediated recombination were similar to procedures described (15) . To detect the presence of the targeted sequence, primers 5 ¶-TTCGGGT-GGGAGAATCAGAC-3 ¶ (T1) and 5 ¶-GGATCTCTCCCCATTCACCA-3 ¶ (T2) were used (Fig. 1A) . To detect the first two exons of Mrad9, primers 5 ¶-CCGGGTGAACCAATAAGGAA-3 ¶ (D1) and 5 ¶-AAGGAAGCAGGCATAGG-CAG-3 ¶ (D2) were used. PCR conditions were 95jC for 5 min to initially denature DNA, then 35 cycles at 95jC for 30 s, 55jC for 1 min, 72jC for 1 min, and a final extension at 72jC for 5 min. The final reaction mix (25 AL) contained 1Â Easy Taq SuperMix (TransGen Biotech Co), 1 AL genomic DNA, and 10 pmol of each primer. All of the animal handling for these protocols and in the following procedures was performed following methods approved by the Institutional Animal Care and Use Committee at the Institute of Biophysics, Chinese Academy of Sciences.
Semiquantitative genomic PCR. To examine Mrad9-deletion efficiency in mouse keratinocytes, one sequence downstream of the targeted site was used as template for a DNA loading control. The DNA fragment was generated by PCR using primers 5 ¶-TTCTGTCCTTTCCCCTTGCA-3 ¶ and 5 ¶-GGAGGAAAGCAACAAGTCCT-3 ¶. PCR conditions were the same as described above for genotyping except 60jC was used as the annealing temperature and 28 cycles were run. Genotyping for the successful targeting and deletion of Mrad9 was carried out with the same method described above.
Reverse transcription-PCR. Total RNA was prepared from epidermis of newborn mice using the RNeasy Mini kit (QIAGEN), as described by the manufacturer. For reverse transcription-PCR (RT-PCR), 2 Ag total RNA were reverse transcribed in a 20 AL reaction volume to form cDNA using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen). PCR amplification of Mrad9 was performed using 1 AL of the cDNA generated above and the primer pair: 5 ¶-CTCTATCTGGAACCCTTGAAGGACG-3 ¶ and 5 ¶-CGCAATAAGTGAGGGCATGAGG-3 ¶. Results were normalized to the amount of a PCR-amplified GAPDH fragment using 1 AL of cDNA and primers 5 ¶-GCAAAGTGGAGATTGTTGCC-3 ¶ and 5 ¶-CCGTATTCATTGTCA-TACCA-3 ¶. For Mrad9 PCR amplification, there was an initial DNA template denaturation at 95jC for 3 min, then 30 cycles of 95jC for 30 s, 60jC for 1 min, 72jC for 30 s, and a final extension at 72jC for 3 min. GAPDH PCR conditions were the same as for Mrad9 except the procedure lasted only 20 cycles.
Quantitative real-time RT-PCR. Total RNA and cDNA from mouse epidermis were isolated as described above. Real-time PCR was performed using the LightCycler system with FastStart DNA Master SYBR Green I to label amplified DNA (Roche). A standard curve method of quantification was used to calculate the expression of target genes relative to the housekeeping gene b-actin. Experiments were performed thrice. The following primer pairs were used for the PCR reactions: Mrad9B, 5 ¶-CCCAAAAG-ACTATTTCCCAAG-3 ¶ and 5 ¶-TGTTCACAAGATACAGCTCCAA-3 ¶; p21, 5 ¶-GGAACATCTCAGGGCCGAAAA-3 ¶ and 5 ¶-GAGAGGGCAGGCAGCGTAT-3 ¶; p53, 5 ¶-CAGCACATGACGGAGGTCG-3 ¶ and 5 ¶-CTTCCAGATACTCGGGATA-CAA-3 ¶; b-actin, 5 ¶-GTAAAGACCTCTATGCCAACA-3 ¶ and 5 ¶-GGACTCAT-CGTACTCCTGCT-3 ¶. PCR procedures for the these genes were template denaturation at 94jC for 5 min, then 40 cycles of 94jC for 15 s, 60jC for 20 s, 72.0 C for 13 s, and a final extension at 72jC for 3 min.
Western blotting. For preparing protein from epidermis, full-thickness skin removed from newborn mice was treated with 0.25% trypsin overnight at 4jC. The epidermis was peeled off from the dermis and dispersed in lysis buffer. To prepare cell lysate, keratinocytes incubated for 3 d were either left untreated or treated for 24 h with 0.15 Ag/mL DMBA (Sigma). Then, the cell Figure 1 . Mrad9 deletion in keratinocytes. A, maps of original, targeted and deleted Mrad9 genomic DNA fragments. Black boxes, exons; thin lines, introns as well as DNA sequences surrounding Mrad9 . Locations of primer pairs for detecting the targeting (T1/T2), deletion (D1/D2) of the first two exons and DNA loading control (S1, S2) are marked. B, PCR genotyping of Mrad9 deletion in mouse tissues. Top, results using primers T1/T2 and D1/D2, and mouse tail DNA as template. Bottom, the genotyping results using various mouse tissues. The deleted signature DNA band was only observed in tissues bearing keratinocytes. gl stomach, gland stomach. C, PCR-genotyping on skin keratinocytes incubated for 3 d after isolation. The PCR was semiquantitative and revealed the Cre efficiency to delete Mrad9 . A PCR result using S1/S2 primers is given on the top as the DNA loading control. lysate was prepared in 1 Â SDS-sample buffer, from a final concentration of 10 4 cells per microliter. Fifty micrograms of protein were resolved on a 10% SDS-PAGE gel, and proteins were transferred to a polyvinylidene difluoride membrane. The membrane was probed consecutively with primary and peroxidase-conjugated secondary antibodies, and the signal was detected using the SuperSignal West Pico Chemiluminescence Substrate system (Pierce). Primary and secondary antibodies used in this study are mouse anti-phospho-H2AX (Upstate), mouse anti-tubulin (Sigma), mouse anti-p21 (Santa Cruz), mouse anti-p53 (Oncogene), mouse anti-RAD9 (BD), rabbit anti-actin (Sigma), rabbit anti-RAD9B (prepared by Dr. Lieberman's laboratory), peroxidase-conjugated anti-mouse IgG (A9044; Sigma), and peroxidase-conjugated anti-rabbit IgG (A9169; Sigma).
DMBA-induced skin tumor formation. A published method, with minor modifications, was used to induce skin tumors in mice by the application of DMBA (17) . The backs of mice (7-to 8-wk-old) were shaved 2 d before tumor induction. Then, one side of the shaved dorsal skin was painted with 2 Ag DMBA (Sigma) in 0.1 mL acetone twice a week (Wednesday and Sunday); the other side was treated with only acetone as a control. Scoring for tumors was performed weekly. Positive tumor formation was determined using the following criteria: tumors 1 mm or larger in diameter were maintained for 2 wk. After positive identification of tumor formation, DMBA treatment was stopped. The longest painting was 25 wk, then the mice were observed for tumor formation for 5 more wk. All mice were also examined for the appearance of DMBA-induced pigment deposition spots. Criteria for the occurrence of pigment spots were detection of 10 or more spots, 1 mm or larger in diameter, on one side of the dorsal skin. In contrast, mice were considered pigmentation negative when no spots appeared or spots were smaller than 0.5 mm in diameter and fewer than 8 appeared. Overall, 70% of the negative mice contained no pigmentation spots.
Histologic analysis and immunohistochemistry. Dorsal skin samples and tumors were fixed in 4% paraformaldehyde at 4jC overnight, embedded in paraffin, and sectioned as 8-Am slices. The sectioned tissues on slides were stained with H&E (18, 19) or Van Gieson's (VG) Solution (20) . Immunohistochemical staining was carried out using a kit (ImmunoCruz Staining Systems, Beijing Zhongshan Golden Bridge Biotechnology). The endogenous peroxidase activity in the specimens was blocked by treatment with 0.3% H 2 O 2 and samples were then rinsed with PBS. The specimens were probed consecutively with primary antibodies against Keratin 14 (BAbCo), secondary antibody biotin-conjugated goat anti-rabbit IgG, and horseradish peroxidase-streptavidin complex, then visualized by diaminobenzidine. Afterwards, sections were counterstained with hematoxylin (18, 19) .
PCR analysis of tumor and normal cells isolated by laser capture microdissection. Paraformaldehyde-fixed, paraffin-embedded tumors and normal skin tissues were sectioned and stained with H&E. To determine the status of Mrad9 in presumably Mrad9 nondeleted (Tar/Tar) or deleted (À/À) tumors, microdissection of tumor and adjacent normal cells from thin sections on slides was performed using a Leica laser microdissection system (Leica As LMD). Dissected cells were digested overnight with proteinase K. DNA isolation and PCR were carried out as described above.
Preparation and in vitro culture of keratinocytes. Full-thickness skin removed from newborn mice was treated with 0.25% trypsin overnight at 4jC. The epidermis was peeled off from the dermis and dispersed by stirring into single cells that were then suspended in Keratinocyte-SFM medium with supplements (Invitrogen). Cells were first incubated in dishes coated with collagen type I at 34jC in 5% CO 2 for 12 h to allow cells to attach to the bottom. Afterwards, unattached cells were removed by washing with PBS. Attached cells were further cultured in fresh medium, which was replaced every 2 d.
Proliferation assay. Keratinocytes were isolated as described and seeded into 12-well plates (3.5 Â 10 5 cells per well) containing Keratinocyte-SFM medium with supplements. Cells were counted every 2 d. The effect of antioxidant treatment was assessed by culturing Keratinocytes in medium containing 1 Amol/L epigallocatechin gallate (EGCG) added initially on the second day of culturing, and included in the fresh medium used during routine maintenance of the cells.
Cell cycle analyses. The profile of cells in different phases of the cell cycle was determined using previously established methods (21) . For a simple analysis of cell cycle distribution, 1 Â 10 7 keratinocytes were plated per 10-cm dish. After incubation for 4 d, cells were processed and stained with propidium iodide (PI), then analyzed by a FACSCalibur (Becton Dickinson). To assess DNA synthesis, 10 Amol/L BrdUrd was added to medium and cells were pulse labeled for 40 min. Cells were then processed and probed with FITC-conjugated anti-BrdUrd antibody (Becton Dickinson) and stained with PI. Flow cytometric analyses were performed on a FACSCalibur.
Apoptosis assays. Keratinocytes, were cultured for 5 d and trypsinized for 10 min using 0.1% trypsin at 37jC (Sigma), washed twice with cold PBS, then resuspended in 1Â binding buffer [10 mmol/L HEPES (pH 7.4), 140 mmol/L NaCl, and 2.5 mmol/L CaCl 2 ] at a concentration of 1 Â 10 6 cells per milliliter. Then cells were stained with Annexin V-FITC (Jingmei Biotech) and PI for 15 min at room temperature, before flow cytometric analysis.
Neutral comet assay. Keratinocytes were first cultured in standard medium for 2 d, then incubated in medium containing 0, 0.01, 0.025, 0.05, or 0.1 Ag/mL DMBA, respectively, for 24 h before analysis. The comet assay was carried out according to the manufacturer's instruction (Trevigen). Briefly, cells at a concentration of 1 Â 10 5 /mL were mixed gently with premelted low-temperature-melting agarose at a volume ratio of 1 to 10 (v/v) and spread on glass slides. The slides were then submerged in precooled neutral lysis buffer at 4jC for 30 min. After rinsing, the slides were equilibrated in Tris-borate EDTA solution, electrophoresed at 1.0 V/cm for 20 min, and then stained with PI. Fluorescence images for at least 50 nuclei were captured using a Nikon microscope and analyzed by CASP-1.2.2 software (University of Wroclaw) for tail moment (i.e., the geometric mean of fluorescence on the tail from the nucleus).
Statistical analysis. All statistical analyses were performed using statistical software package SAS Version 9.1.3 (22) . The m 2 test was used to compare genotype ratio for newborn pups derived from matings between Mrad9 +/À mice. The Kaplan-Meier PL method (23) was used for comparison of the relative risks of tumor development induced by DMBA among the mice with the three Mrad9 genotypes. We designed the tumor development experiment to meet a set of conditions so the Log-Rank Test in the KaplanMeier PL method could be used, and the number of animals used was reduced but results with statistical significance still could be achieved (refer to Results; ref. 24) . The Student's t test was performed to determine statistical significance of the differences for the comet assay. In all the above analyses, a P value of <0.05 was considered statistically significant.
Results
Targeted deletion of Mrad9 in mouse keratinocytes.
Mrad9
À/À mice die during embryonic development, but relative to wild-type controls, Mrad9 +/À animals have no overt defects in gross morphology or health up to age 1.5 years (15) . In this report, we describe the development of viable mice with a specific deletion of Mrad9 in keratinocytes. These animals were made by crossing mice containing loxP targeted to Mrad9 (15) with mice in which Cre transcription is under the control of the K5 promoter, specifically activated in keratinocytes starting on day 14.5 dpc (16) . After repeated backcrosses, homologous Cre genotypes were obtained in mice with three different Mrad9 genotypes (Fig. 1A  and B) . Cre homozygous status of the mice was determined by crossing them with 2 mice bearing no Cre, which produced at least 15 Cre-positive pups and no Cre-negative pups (data not shown Deletion of Mrad9 occurred exclusively in tissues (skin, forestomach, eye, and esophagus) that contain keratinocytes (Fig. 1B) . Notably, PCR using DNA templates from Cre +/+ Mrad9 Tar/Tar mouse skin or isolated skin keratinocytes yielded both Mrad9-deleted as well as Mrad9-targeted signature bands (Fig. 1B and C) , indicating that Mrad9 deletion in skin keratinocytes was not complete, or there was a significant contamination of other types of cells. To exclude the possibility that the targeted signature bands mainly derived from contaminating nonkeratinocytes, the percentage of cells containing keratin 14 was assessed by flow cytometry. The isolated Cre +/+ Mrad9 Tar/Tar skin keratinocytes stained with antikeratin 5 antibody were 96% keratin 14 positive (data not shown). We also reperformed the PCR using the T1/T2 primer pair and DNA templates from keratinocytes with 5 cycles less of reaction. For these conditions, the targeted signature bands were reduced to 1 We also monitored Mrad9 mRNA and protein levels in pup skins (Fig. 1D) Inhibitory Role of Rad9 in Skin Tumor Development www.aacrjournals.org each litter consisting of 3 mice with 3 different Mrad9 genotypes, respectively, and identical sex, either female (10 liters) or male (6 liters). Under this setting, Log-Rank Test in the Kaplan-Meier PL method can be used for the statistical analysis on the significance of differences of tumor development among the three groups of animals (22, 23) . DMBA is a chemical carcinogen that can induce tumors efficiently (25, 26) . Two micrograms of DMBA in 0.1 mL acetone were painted onto shaved mouse skin twice a week for 25 weeks. Skin tumors began to appear on Mrad9 À/À mouse skin after DMBA treatment for 15 weeks, whereas tumor onset occurred 25 and 27 weeks after the start of DMBA treatment in Mrad9 +/À and Mrad9 +/+ mice, respectively ( Fig. 2A and B) . Staining skin specimens with H&E or antikeratin 14 showed that the tumors were derived from keratinocytes and possessed characteristics of papillomas ( Fig. 2C; ref. 27 ). Kaplan-Meier PL method (23) was used for comparison of the relative hazards of tumor development induced by DMBA among the three genotypes of mice. The rate of tumor development in Mrad9 À/À mice was significantly higher than in Mrad9 +/À and Mrad9 +/+ animals (P = 0.0004 and P = 0.0003, respectively, Log-Rank Test). Although Mrad9 +/À mice tended to be more prone to induced tumorigenicity than Mrad9 +/+ mice, the difference is not statistically significant (P = 0.4088, Log-Rank Test).
Therefore, lower levels of Mrad9 caused by haploinsufficiency did not cause significantly increased cancer development, relative to wild-type controls.
Because the Cre-mediated Mrad9 deletion was not complete, to confirm the importance of Mrad9 in tumor inhibition, tumor and nearby normal cells were isolated using laser capture microdissection, and their genomic DNA was subjected to PCR. All five examined tumors from Mrad9 À/À mice were Mrad9 À/À , whereas the normal cells on the sides of the tumors still contained undeleted but targeted Mrad9 (Fig. 2D) as expected, indicating that Mrad9 indeed plays a significant role in preventing tumor development. Under this experimental setting, the number of induced tumors for all three Mrad9 genotypes was 1 or 2, and differences between mice with different Mrad9 genotypes were not observed.
Mrad9 deletion alters the cell cycle profile of keratinocytes and increases DNA damage. Because Rad9 plays important roles in DNA repair and cell cycle checkpoint controls, two processes important for maintaining genomic integrity and preventing carcinogenesis, we investigated these processes in keratinocytes bearing an Mrad9 deletion. Skin keratinocytes were isolated from 1-day-old pups. The cells were grown in defined Keratinocyte-SFM 
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Cancer Res 2008; 68: (14) . July 15, 2008 medium (Life Technologies, Inc.). The number of cells with each of the three genotypes dropped to <30% of the seeded (3.5 Â 10 5 per well) level after the first 2 days of incubation. Subsequently, the total number of wild-type cells increased between day 2 and 6, then cell proliferation slowed down ( Fig. 3A; data not shown). In contrast, the total number of Mrad9 À/À cells continued to decrease ( Fig. 3A; data not shown). The Mrad9 À/À cells did not stop decreasing in number and did not begin to grow after extended culturing (data not shown). There were two types of Mrad9 heterozygous pups when mouse tail DNA was used for genotyping 1 day after birth, one with a high frequency of deletion of the Mrad9-targeted allele and the other with a low level of deletion (PCR data not shown). However, when genotyped again in 20-day and 2-month-old mice, there was only the latter type of deletion (data not shown). Furthermore, the cells isolated from all newborn Mrad9 +/À pups were found to have the latter deletion type after being cultured 3 days and then genotyped. The reason for having the subtle differences among newborn Mrad9 +/À pups was not understood, but for the succinctness of experiments, the differences were not distinguished for the rest of the study.
We tested whether reduction in number of Mrad9-deleted keratinocytes was caused by DNA lesions induced by reactive oxygen species (ROS) because it is known that Rad9 plays an important role in DNA damage repair. Conventionally, cells are cultured at 20% O 2 . Incubation at this O 2 concentration loads cells with a higher O 2 tension (thus higher ROS level) than within animals (28) (29) (30) . We used the antioxidant EGCG to scavenge oxidative-free radicals to assess the effect of the high oxygen tension present during cell culture, relative to in vivo in the animal, on cell proliferation. The addition of 1 Amol/L of the antioxidant EGCG to the medium changed the direction of the cell growth curves of Mrad9 À/À and Mrad9 +/À keratinocytes upward from day 6 (Fig. 3A) . Therefore, high O 2 tension was a major cause for the cell number reduction observed. Growth of the wild-type cells also slowed down in the EGCG-containing medium, an established inhibitory effect of the drug on cell proliferation (31, 32) .
Flow cytometric analyses of PI-stained keratinocytes indicated that more Mrad9 À/À and Mrad9 +/À cells, compared with the wild-type controls, accumulated in late S phase (Fig. 3B) . A measurement of BrdUrd uptake by replicative S phase cells in combination with DNA content via PI staining in individual cells can reveal more information on cell cycle distribution. Therefore, we investigated cell cycle profiles in more detail by pulse labeling with BrdUrd and staining cells after 4 days of incubation. A major population of Mrad9 À/À and Mrad9 +/À cells with DNA content in the range primarily of late S phase was not labeled by BrdUrd, and there were fewer BrdUrd-positive Mrad9 À/À and Mrad9 +/À cells than wild-type cells in S phase (Fig. 3C) . The BrdUrd-negative cells with late S phase DNA content means that the cells were arrested in late S phase. Based on the above data, we conclude that the arrest of cells in late S phase is an important cause for the cell We used the neutral comet assay to detect double-strand breaks (DSBs) in DNA. There were significantly more DSBs in incubated Mrad9 +/À cells than in wild-type cells, and more DSBs in Mrad9
À/À cells than in Mrad9 +/À cells (Fig. 4A) . Therefore, Mrad9 is critical for maintaining genomic integrity, and there is a dosagedependent effect. H2AX phosphorylation level is another established indicator of DNA DSBs. Consistent with the comet assay results, H2AX phosphorylation levels from lysates of Mrad9 À/À cells as well as Mrad9 +/À cells were much higher than in wild-type cell lysates (Fig. 4C ). Interestingly, H2AX phosphorylation level from Mrad9 À/À cells (arbitrary number 9) was lower than that from Mrad9 +/À cells (arbitrary number 19). H2AX phosphorylation occurs predominantly in S phase and G 2 -M phase cells during in vitro culturing (33) . The lower ratio of normal S phase cells is likely a cause for the relatively lower H2AX phosphorylation level compared with that of Mrad9 +/À cells (Fig. 3C) . In spite of possible influence by the changed cell cycle distribution, the overall H2AX phosphorylation level in Mrad9 À/À cells was still higher than that in wild-type cells (arbitrary number 1). As we showed above, tumors only appeared after DMBA treatment. Therefore, we asked if DMBA treatment causes more DSBs in Mrad9-deficient cells than in wild-type cells. As predicted, incubation in medium containing 0.02 to 0.05 Ag/mL DMBA induced significantly more DSBs in Mrad9-deficient cells than in wild-type cells (Fig. 4B) . Further increase in the DMBA concentration to 0.1 Ag/mL greatly enhanced tail moment and coefficient variance of tail moment in the Mrad9 À/À cells. The dramatic increases in both tail moment and its coefficient variance were because a subpopulation of Mrad9 À/À cells had very long tails ( Fig. 4B ; data not shown), a characteristic of apoptosis (34) .
No apoptosis was observed in Mrad9 +/À and Mrad9 +/+ cells treated with DMBA.
To confirm the effects of Mrad9 deletion on apoptosis, we stained the same cell populations for Annexin V-FITC and PI to provide supporting evidence. We found that the percentage of apoptotic cells among Mrad9 +/À keratinocytes (7.74%) was higher than that of Mrad9 +/+ cells (6.32%). The percentage of Mrad9 À/À apoptotic cells (10.58%) was higher than that of Mrad9 +/À cells (Fig. 4D) . The inhibitory effect of Rad9 on apoptosis was consistent with previously reported effects on murine embryonic stem cells (35) and chicken DT40 cells (36) .
Effect of Mrad9 deletion on expression of other cell cycle checkpoint genes. Expression of other cell cycle checkpoint genes, including p21, p53, and Rad9B, in Mrad9 À/À and control keratinocytes was assessed by quantitative RT-PCR and Western blotting to gain mechanistic insight into the function of Mrad9. Both heterozygous and homozygous deletion of Mrad9 induced expression of p21, p53, and Rad9B in skin keratinocytes ( Fig. 5A and B). Statistical analyses on the quantitative RT-PCR results indicate that the expression of the three genes in Mrad9 À/À cells is significantly higher than those in Mrad9 +/À and Mrad9 +/+ cells (Fig. 5A ). DMBA treatment (0.15 Ag/mL, 24 h) increased the levels of p21 and p53 proteins in cells with each of the three genotypes (Fig. 5B) . The same treatment also enhanced Mrad9B protein level in wild-type cells but not obviously in Mrad9 À/À and Mrad9 +/À cells. These results suggest that the genomic DNA damage stress response system is increased in cells with a deletion of Mrad9. Susceptibility of Mrad9 À/À mice to the development of aging skin. In the same set of mice used for tumor development experiments, DMBA treatment to skin readily induced skin pigment deposition in Mrad9 À/À mice (Fig. 5A ). Within the DMBA treatment experimental period (30 weeks), skin pigment deposition occurred on 81.3% of Mrad9 À/À , 25% of Mrad9 +/À , and 12.5% of Mrad9 +/+ mice (Fig. 5B) . Pigment deposition occurred in 2 to 5 weeks after tumor formation in most mice and after the end of DMBA treatment in mice bearing any of the three genotypes (data 
Cancer Res 2008; 68: (14) . July 15, 2008 not shown). H&E and VG staining on skin specimens showed that pigment particles in the dermis were abnormally increased ( Fig. 5C and D) , hair follicle number significantly decreased, and epidermis atrophied in Mrad9 À/À mice. These phenotypes indicate that the skin of Mrad9 À/À mice aged readily in response to DMBA treatment. However, the phenotypes did not appear without DMBA treatment (data not shown), suggesting that they are mediated by DNA damage.
Discussion
The Rad9 gene is evolutionarily conserved from yeast to human and critical for cell cycle checkpoint controls as well as DNA repair (6, 7) . Its role as a tumor suppressor has not been reported thus far, although many DNA repair and cell cycle checkpoint genes are required for preventing tumorigenesis. Here, we report the establishment of a conditional Mrad9 knockout model using mouse keratinocytes to examine whether Mrad9 is inhibitory to tumor formation and the mechanisms involved (Fig. 1) . We showed that Mrad9 is required for suppressing skin tumor formation induced by the DNA-damaging agent DMBA (Fig. 2) . Furthermore, we show that Mrad9 also plays a key role in preventing skin aging induced by DMBA treatment (Fig. 6) .
Although DMBA treatment enhanced the incidence of papillomas in Mrad9 deleted skin keratinocytes statistically significantly more than in wild-type keratinocytes, the Mrad9 deletion alone did not lead to an increase in spontaneous tumor formation. DNA repair, cell cycle checkpoint controls, and apoptosis are three key Inhibitory Role of Rad9 in Skin Tumor Development www.aacrjournals.org functions in preventing the formation of primary tumors. There is an abundance of evidence indicating that Rad9 participates in multiple DNA repair pathways (8, (37) (38) (39) (40) (41) (42) (43) and cell cycle checkpoints (15, (44) (45) (46) . Both antiapoptotic and proapoptotic roles were reported using different human and animal cell lines (36, (47) (48) (49) . The roles of Rad9 in DNA repair and apoptosis in keratinocytes have not been reported previously. We illustrated in this study that keratinocytes with Mrad9 deleted at either one or two loci had more DNA DSBs, and the increase of DNA lesions induced by DMBA was more significant in Mrad9-deleted cells than in wildtype controls (Fig. 4) . Therefore, the function of Mrad9 in repairing DNA lesions is likely one key component of the ability of the protein to repress tumorigenesis. Mrad9 deletion led to higher apoptotic keratinocytes in culture either with DMBA treatment or not (Fig. 4C) , thus, apoptosis is not a significant mechanism used by Mrad9 to serve as a gatekeeper to prevent tumor formation in skin keratinocytes.
Human Rad9 protein can bind the p21 promoter region and induce p21 transcription (50) . Here, we showed that Mrad9 deletion highly enhanced p21 expression (Fig. 5A) . However, Mrad9 deletion also induced p53 expression (Fig. 5A ), which could serve as the transactivator of p21 expression. Interestingly, Mrad9 deletion also enhanced Mrad9B (Mrad9 homologue) expression. Because Mrad9 deletion alone did not lead to tumor formation, it is possible that Mrad9B might have at least partially redundant functions related to Mrad9 activity. Treatment with DMBA increased Mrad9B protein level in wild-type keratinocytes but did not further enhance Mrad9B level in Mrad9 À/À and Mrad9 +/À keratinocytes. However, DMBA treatment increased p21 and p53 protein levels in keratinocytes with any of the three Mrad9 genotypes (Fig. 5B) . The Mrad9B level seems to be limited to relatively low abundance compared with p21 and p53 levels, suggesting that the regulation of Mrad9B is different from that of p21 and p53. DMBA treatment also caused mouse skin aging in Mrad9-deleted animals more significantly than in wild-type controls. Skin aging was reflected as increased pigmentation, decreased hair follicles, and atrophied epidermis. In cell culture, Mrad9-deleted keratinocytes have more DSBs and a net negative growth (Fig. 4A) . Detailed examination revealed that many Mrad9-deficient cells were arrested in late S phase and more tended to go into apoptosis (Figs. 3D and 4C) . The Mrad9-deficient cells did not stop replicating, thus the arrest in late S phase and apoptosis are major contributing factors to the negative growth of Mrad9-deleted keratinocytes cultured in vitro. The negative growth was reversed by addition of the antioxidant EGCG to the medium (Fig. 3A) , suggesting that oxidative free radicals lead to the growth defect, probably due to an enhancement in the frequency of DNA lesions. Under in vivo conditions where oxygen tension is lower and keratinocytes are in a more compatible environment, it is conceivable that extra genomic stress such as DMBA treatment is needed to increase the number of DNA lesions and mediate the proliferation defect.
It is clear from our results that Rad9 affects cell cycle distribution in keratinocytes. How Mrad9 regulates cell cycle checkpoints in keratinocytes and the relationship to the mechanism that arrests Mrad9-deleted keratinocytes in late S phase remain to be addressed. The mechanism underlying the latter novel phenotype, in particular, is worth further investigation.
In summary, we show that Rad9 is important for resisting the development of tumors in keratinocytes, and roles in several molecular mechanisms that stabilize the genome might be involved. This work underscores the need to understand the function of Rad9 and other cell cycle checkpoint or DNA repair proteins, especially in terms of their effect on tumorigenesis and potential for translational effect in the clinic.
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